Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.58 |
| ▸ | SYK | P43405 | 3/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.43 |
| ▸ | JUN | P05412 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576366 | 0.79 | CYP11B1 (0.53) | ROCK1MAP3K5MAP4K1 | |
| SCHEMBL3338544 | 0.77 | AURKA (0.57) | MKNK2SYKROCK1JAK3MAP3K5 | |
| Benzene SCHEMBL28188863 | 0.76 | MAP3K5 (0.60) | MKNK2SYKROCK1JAK3MAP3K5 | |
| SCHEMBL31381352 | 0.76 | MAP3K5 (0.60) | MKNK2SYKROCK1JAK3MAP3K5 | |
| SCHEMBL27770482 | 0.76 | MAP3K5 (0.60) | MKNK2SYKROCK1JAK3MAP3K5 | |
| SCHEMBL167891 | 0.76 | MAP3K5 (0.60) | MKNK2SYKROCK1JAK3MAP3K5 | |
| SCHEMBL3965297 | 0.76 | JAK3 (0.53) | MKNK1MKNK2SYKJAK3MAPK1 | |
| SCHEMBL5262847 | 0.76 | CDK4 (0.73) | SYKJAK3ALDH1A1 | |
| SCHEMBL3756770 | 0.75 | MAPK10 (0.70) | MKNK1MKNK2JAK3MAPK10MAPK8 | |
| SCHEMBL4573935 | 0.75 | MAP3K5 (0.58) | MKNK2SYKROCK1JAK3MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MKNK1 56/4885MKNK2 47/4885SYK 721/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MKNK1 56/4885MKNK2 47/4885SYK 721/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MKNK1 56/4885MKNK2 47/4885SYK 721/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MKNK1 56/4885MKNK2 47/4885SYK 721/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MKNK1 56/4885MKNK2 47/4885SYK 721/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | MKNK1 305/4885MKNK2 215/4885SYK 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.